Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: Potential benefits and possible risks

Expert Opinion on Biological Therapy

Volumn 11, Issue 5, 2011, Pages 655-666

  Sangiolo, Dario ^a   Leuci, Valeria ^a   Gallo, Susanna ^a   Aglietta, Massimo ^a   Piacibello, Wanda ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Gene modified T cells; GVHD; hematopoietic cell transplantation; retroviral vector

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; NERVE GROWTH FACTOR RECEPTOR; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; THYMIDINE KINASE;

ACTIVE IMMUNIZATION; ALLOIMMUNITY; ANTIVIRAL ACTIVITY; CELL FUNCTION; CELL PROLIFERATION; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG SAFETY; GENE; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SUICIDE GENE THERAPY; T LYMPHOCYTE; TREATMENT RESPONSE; VIRUS INFECTION;

APOPTOSIS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSFECTION;

SIMPLEXVIRUS;

EID: 79953860671     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.565325     Document Type: Review

References (100)

1. Storb R Reduced-intensity conditioning transplantation in myeloid malignancies. Curr Opin Oncol 2009;21(Suppl 1):S3-5
2. Appelbaum FR Hematopoietic cell transplantation as a form of immunotherapy. Int J Hematol 2002;75:222-7 (Pubitemid 43014052)
3. Aglietta M, Barkholt L, Schianca FC, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. Biol Blood Marrow Transplant 2009;15:326-35
4. Carnevale-Schianca F, Cignetti A, Capaldi A, et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 2006;107:3795-803
5. Childs R, ChernoffA, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-8
6. Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004;103:790-5 (Pubitemid 38129534)
7. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767-76 (Pubitemid 38129531)
8. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-58 (Pubitemid 38351787)
9. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83:1971-9 (Pubitemid 24107924)
10. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-41
11. Caldas C, Ambinder R Epstein-Barr virus and bone marrow transplantation. Curr Opin Oncol 1995;7:102-6
12. O'Reilly RJ, Small TN, Papadopoulos E, et al. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. Springer Semin Immunopathol 1998;20:455-91 (Pubitemid 28550111)
13. van de Donk NW, Kroger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37:1135-41 (Pubitemid 43871524)
14. Bonini C, Ciceri F, Marktel S, Bordignon C Suicide-gene-transduced T-cells for the regulation of the graft-versus-leukemia effect. Vox Sang 1998;74(Suppl 2):341-3 (Pubitemid 28379803)
15. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-24 (Pubitemid 27421983)
16. Bordignon C, Bonini C, Verzeletti S, et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 1995;6:813-19
17. Ciceri F, Bonini C, Gallo-Stampino C, Bordignon C Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Cytotherapy 2005;7:144-9 (Pubitemid 40872749)
18. Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007;109:4698-707 (Pubitemid 46827761)
19. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009;10:489-500
20. Champlin R, Bensinger W, Henslee-Downey J, et al. Phase I/II study of thymidine kinase (tk)-transduced donor lymphocyte infusions (DLI) in patients with hematologic malignancies. Blood 1999;94(Suppl 1):abstract 1448
21. Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001;97:63-72 (Pubitemid 32061243)
22. Burt RK, Drobyski WR, Seregina T, et al. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hematol 2003;31:903-10 (Pubitemid 37211375)
23. Marktel S, Magnani Z, Ciceri F, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003;101:1290-8 (Pubitemid 36182498)
24. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62 (Pubitemid 20069191)
25. Cavalieri S, Cazzaniga S, Geuna M, et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 2003;102:497-505 (Pubitemid 36841966)
26. Kaneko S, Mastaglio S, Bondanza A, et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009;113:1006-15
27. Sauce D, Tonnelier N, Duperrier A, et al. Influence of ex vivo expansion and retrovirus-mediated gene transfer on primary T lymphocyte phenotype and functions. J Hematother Stem Cell Res 2002;11:929-40 (Pubitemid 36139774)
28. Bondanza A, Valtolina V, Magnani Z, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 2006;107:1828-36 (Pubitemid 43289360)
29. Robinet E, Fehse B, Ebeling S, et al. Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function. Cytotherapy 2005;7:150-7 (Pubitemid 40872750)
30. Naldini L. Inserting optimism into gene therapy. Nat Med 2006;12:386-8
31. Verhoeyen E, Dardalhon V, Ducrey-Rundquist O, et al. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood 2003;101:2167-74 (Pubitemid 36302054)
32. Qasim W, Mackey T, Sinclair J, et al. Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction. Mol Ther 2007;15:355-60 (Pubitemid 46111886)
33. Sauce D, Mercier P, Battini JL, et al. Preferential retroviral-mediated transduction of EBV-and CMV-specific T cells after polyclonal T-cell activation. Gene Ther 2004;11:1019-22 (Pubitemid 38923626)
34. Sauce D, Bodinier M, Garin M, et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 2002;99:1165-73 (Pubitemid 37258302)
35. Bonini C, Bondanza A, Perna SK, et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 2007;15:1248-52 (Pubitemid 46965319)
36. Mavilio F, Ferrari G, Rossini S, et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994;83:1988-97 (Pubitemid 24107926)
37. Lupo-Stanghellini MT, Provasi E, Bondanza A, et al. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther 2010;21:241-50
38. Zhan H, Thrasher A, Farzaneh F, et al. Preparation for a Phase I/II clinical trial of T cell suicide gene therapy following haematopoietic stem cell transplantation in children. Hum Gene Ther 2010;21:509
39. Tey SK, Dotti G, Rooney CM, et al. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007;13:913-24 (Pubitemid 47055386)
40. Di Stasi A, Tey SK, Fujita Y, et al. CASPALLO: phase I clinical trial of allodepleted T cells transduced with inducible caspase 9 suicide gene after haploidentical stem cell transplantation. Mol Ther 2010;18(Suppl 1):abstract 288
41. Griffioen M, van Egmond EH, Kester MG, et al. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica 2009;94:1316-20
42. Introna M, Barbui AM, Bambacioni F, et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther 2000;11:611-20 (Pubitemid 30134304)
43. Serafini M, Manganini M, Borleri G, et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther 2004;15(1):63-76 (Pubitemid 38147189)
44. Sangiolo D, Lesnikova M, Nash RA, et al. Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection. Gene Ther 2007;14:1549-54 (Pubitemid 47570715)
45. Fehse B, Kustikova OS, Li Z, et al. A novel 'sort-suicide' fusion gene vector for T cell manipulation. Gene Ther 2002;9:1633-8 (Pubitemid 35414526)
46. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005;23:6421-8 (Pubitemid 46218853)
47. van Meerten T, Claessen MJ, Hagenbeek A, Ebeling SB. The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. Gene Ther 2006;13:789-97
48. Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 2001;61:3022-6 (Pubitemid 32691949)
49. Preuss E, Treschow A, Newrzela S, et al. TK.007: a novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy. Hum Gene Ther 2010;21:929-41
50. Onodera M. Gene and cell therapy for relapsed leukemia after allo-stem cell transplantation. Front Biosci 2008;13:3408-14 (Pubitemid 351594691)
51. Fehse B, Ayuk FA, Kroger N, et al. Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells. Blood 2004;104:3408-9 (Pubitemid 39507166)
52. Urbano-Ispizua A, Rozman C, Pimentel P, et al. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood 2001;97:383-7 (Pubitemid 32060321)
53. Dembic Z, Haas W, Weiss S, et al. Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 1986;320:232-8 (Pubitemid 16040238)
54. Kessels HW, Wolkers MC, van den Boom MD, et al. Immunotherapy through TCR gene transfer. Nat Immunol 2001;2:957-61 (Pubitemid 32976169)
55. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9 (Pubitemid 44547756)
56. Heemskerk MH, Hoogeboom M, de Paus RA, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 2003;102:3530-40 (Pubitemid 37409367)
57. Mutis T, Blokland E, Kester M, et al. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood 2002;100:547-52 (Pubitemid 34761118)
58. Brenner MK, Okur FV. Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program 2009;1:675-81
59. Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005;106:3062-7 (Pubitemid 41565901)
60. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001;2:962-70 (Pubitemid 32976170)
61. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86:10024-8 (Pubitemid 20030768)
62. Kershaw MH, Darcy PK, Trapani JA, Smyth MJ. The use of chimeric human Fc? receptor I to redirect cytotoxic T lymphocytes to tumors. J Leukoc Biol 1996;60:721-8 (Pubitemid 27041660)
63. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004;172:104-13 (Pubitemid 38020461)
64. Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol 2002;20:70-5 (Pubitemid 34044918)
65. Kershaw MH, Westwood JA, Parker LL, et al. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-15 (Pubitemid 44703776)
66. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112:2261-71
67. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;21:929-41
68. Brentjens R, Yeh R, Bernal Y, et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a Phase I clinical trial. Mol Ther 2010;18:666-8
69. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005;202:379-86 (Pubitemid 41126955)
70. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-5 (Pubitemid 26150682)
71. Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008;112:3574-81
72. Dey BR, Spitzer TR Current status of haploidentical stem cell transplantation. Br J Haematol 2006;135:423-37 (Pubitemid 44583409)
73. Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999;93:467-80 (Pubitemid 29035728)
74. Schub A, Schuster IG, Hammerschmidt W, Moosmann A. CMV-specific TCR-transgenic T cells for immunotherapy. J Immunol 2009;183:6819-30
75. Jurgens LA, Khanna R, Weber J, Orentas RJ. Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: a novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma. J Clin Immunol 2006;26:22-32 (Pubitemid 43112623)
76. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360:436-42 (Pubitemid 34880139)
77. Melenhorst JJ, Solomon SR, Shenoy A, et al. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J Immunother 2006;29:436-3; discussion 365-6
78. Muul LM, Candotti F. Immune responses to gene-modified T cells. Curr Gene Ther 2007;7:361-8 (Pubitemid 47595778)
79. Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 2003;101:2563-9 (Pubitemid 36857614)
80. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-23 (Pubitemid 26057556)
81. Riddell SR, Bleakley M, Nishida T, et al. Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transplant 2006;12(1 Suppl 1):9-12 (Pubitemid 43034113)
82. Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007;109:4708-15 (Pubitemid 46827762)
83. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006;107:2294-302 (Pubitemid 43345547)
84. Mercier-Letondal P, Deschamps M, Sauce D, et al. Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response? Hum Gene Ther 2008;19:937-50
85. Garin MI, Garrett E, Tiberghien P, et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 2001;97:122-9 (Pubitemid 32061251)
86. Mastaglio S, Stanghellini MT, Bordignon C, et al. Progress and prospects: graft-versus-host disease. Gene Ther 2010;17:1309-17
87. Chalmers D, Ferrand C, Apperley JF, et al. Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol Ther 2001;4:146-8 (Pubitemid 32776506)
88. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-19 (Pubitemid 37296260)
89. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010;16:198-204
90. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010;467:318-22
91. Recchia A, Bonini C, Magnani Z, et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 2006;103:1457-62 (Pubitemid 43191187)
92. Newrzela S, Cornils K, Li Z, et al. Resistance of mature T cells to oncogene transformation. Blood 2008;112:2278-86
93. Brewin J, Mancao C, Straathof K, et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 2009;114:4792-803
94. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103:17372-7 (Pubitemid 44788976)
95. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009;326:818-23
96. Xue S, Gao L, Gillmore R, et al. WT1-targeted immunotherapy of leukaemia. Blood Cells Mol Dis 2004;33:288-90 (Pubitemid 39446501)
97. Sadovnikova E, Jopling LA, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 1998;28:193-200 (Pubitemid 28048290)
98. Bendle GM, Linnemann C, Hooijkaas AI, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 2010;16:565-70
99. Schaft N, Lankiewicz B, Drexhage J, et al. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production. Int Immunol 2006;18:591-601
100. Griffioen M, van Egmond HM, Barnby-Porritt H, et al. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinicalapplication. Haematologica 2008;93:1535-43